A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

NCT07525817 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Mature B-Cell Lymphoma

Interventions

DRUG: Pirtobrutinib

Sponsor

Ou Bai, MD/PHD